Replidyne to Report First Quarter 2008 Earnings
29 Aprile 2008 - 2:30PM
PR Newswire (US)
LOUISVILLE, Colo., April 29 /PRNewswire-FirstCall/ -- Replidyne,
Inc. (NASDAQ:RDYN) announced today that it will hold a conference
call on Wednesday, May 7, 2008 at 4:45 P.M. ET to report first
quarter 2008 earnings. On Thursday, May 8, 2008 at 4:00 P.M. ET
Replidyne will host its annual shareholder meeting at Company
headquarters at 1450 Infinite Drive in Louisville, CO. Earnings
conference call information is as follows: Kenneth J. Collins,
President and CEO, and other members of Replidyne's management team
will discuss earnings results via conference call and webcast on
Wednesday, May 7, 2008, at 4:45 P.M. ET. Callers may participate in
the conference call by dialing 866-770-7125 (domestic) or
617-213-8066 (international), and providing the passcode 79991920.
To access the live webcast, please log on to the Company's website
at http://www.replidyne.com/ and go to the Investor Relations
section. A replay of the conference call will be available
approximately one hour after completion of the call through
Wednesday, May 21, 2008 at midnight. Callers may access the replay
by dialing 888-286-8010 (U.S. participants) or 617-801-6888
(international participants). The audio replay passcode is
81984297. To access a replay of the webcast, visit the Investor
Relations section of the Company's website at
http://www.replidyne.com/. About Replidyne, Inc. Replidyne is a
biopharmaceutical company focused on discovering, developing,
in-licensing and commercializing innovative anti-infective
products. Replidyne's most advanced product candidate, faropenem
medoxomil, is a novel oral community antibiotic, expected to be
appropriate for use as a first-line antibiotic for treatment of
respiratory and skin infections in adult and pediatric patients.
Replidyne's investigational antibacterial agent REP3123 targets
Gram-positive C. difficile bacteria and C. difficile Infection
(CDI). Replidyne is pursuing the development of other novel
anti-infective programs based on its DNA replication inhibition
technology and its in-house discovery research. Safe Harbor This
press release contains plans, intentions, objectives, estimates and
expectations that constitute forward-looking statements about
Replidyne, Inc. that involve significant risks and uncertainties.
Actual results could differ materially from those discussed due to
a number of factors including, the success and timing of
pre-clinical studies and clinical trials; the Company's ability to
obtain a new partner for faropenem on acceptable terms; the
Company's ability to obtain and maintain regulatory approval of
product candidates and the labeling under any approval that may be
obtained; plans to develop and commercialize product candidates;
the loss of key scientific or management personnel; the size and
growth of the potential markets for the Company's product
candidates and the Company's ability to serve those markets;
regulatory developments in the U.S. and foreign countries; the rate
and degree of market acceptance of any future products; the
accuracy of Company estimates regarding expenses, future revenues
and capital requirements; the Company's ability to obtain and
maintain intellectual property protection for our product
candidates; the successful development of the Company's sales and
marketing capabilities; the success of competing drugs that are or
become available; and the performance of third party manufacturers.
These and additional risks and uncertainties are described more
fully in the Company's most recent Form 10-K filed with the SEC
under the Securities Exchange Act of 1934. Copies of filings made
with the SEC are available through the SEC's electronic data
gathering analysis and retrieval system (EDGAR) at
http://www.sec.gov/. All forward-looking statements made in the
press release are made as of the date hereof and the Company
assumes no obligation to update the forward-looking statements in
the document. DATASOURCE: Replidyne, Inc. CONTACT: Sabrina B. Oei,
Dir. Investor & Public Relations of Replidyne, Inc.,
+1-303-996-5535 Web site: http://www.replidyne.com/
Copyright
Grafico Azioni Replidyne (MM) (NASDAQ:RDYN)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Replidyne (MM) (NASDAQ:RDYN)
Storico
Da Mag 2023 a Mag 2024
Notizie in Tempo Reale relative a Replidyne (MM) (NASDAQ): 0 articoli recenti
Più Replidyne (MM) Articoli Notizie